The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women

Bassol, Susana; Carranza-Lira, Sebastián; Celis-González, Cuauhtémoc; Santoyo, S; Murillo, Alfonso; Martínez, Norma; Santos, Javier; Llaca, Victoriano; Loza, F. Rio de la; Zarain, Jesus; Fonseca, Ângela Maggio da; Camargos, Aroldo F.; Baracat, Edmund Chada; Sá, Marcos F.da; Bayo, Juana; Adaro, Liliana; Gurucharri, Carlos; Murga, M.; Siseles, Néstor; Sayegh, Fabiana; Tempone, Antonio; Tempone, Luis M.; Tozzini, R.; Boccanera, Roberto; Naranjo, Carlos; Sánchez, Fabio; Gómez, Gustavo; Blanco, Stella; Reyes-Marquez, R.; Albrecht, Gerhard; Ríos, Pedro Cano

doi:10.1016/j.maturitas.2004.05.014

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-five studies met the inclusion criteria and were included in the review (Figure 1) . Most of them were randomized trials with an active control (n ¼ 25) , followed by placebo-controlled studies (n ¼ 14) [33][34][35][36][37][38][39][40][41][42][43][44][45][46] and non-comparative studies (n ¼ 6) [47][48][49][50][51][52] . The majority were not head-to-head studies of the HT combinations compared in this review.…”

Section: Resultsmentioning

confidence: 99%

“…Study discontinuation rates due to irregular bleeding were in the range of 0.2-30% for 14 HT combinations in separate studies ( Table 2). Some studies reported a <2% rate of discontinuation due to bleeding for six HT combinations, including oral 1 mg/100 mg E2/P4 45 , 1 mg/0.5 and 2 mg/1 mg E2/NETA 8,10,11,15,48 , 0.5 mg/0.25 mg E2/drospirenone 12 , 0.5 mg/2.5 mg E2/DYD 52 , and transdermal 0.025 mg/0.125 mg E2/NETA 15,43 .…”

Section: Discontinuation Due To Bleedingmentioning

confidence: 99%

See 1 more Smart Citation

Uterine bleeding with hormone therapies in menopausal women: a systematic review

et al. 2020

View full text Add to dashboard Cite

Uterine bleeding is a common reason why women discontinue menopausal hormone therapy (HT). This systematic review compared bleeding profiles reported in studies for continuous-combined HT approved in North America and Europe for moderate to severe vasomotor symptoms in postmenopausal women with a uterus. Non-head-to-head studies showed that uterine bleeding varies by formulation and administration route, with oral having a better bleeding profile than transdermal formulations. Cumulative amenorrhea over a year ranged from 18 to 61% with oral HT and from 9 to 27% with transdermal HT, as reported for continuous-combined HT containing 17b-estradiol (E2)/progesterone (P4) (56%), E2/norethisterone acetate (NETA) (49%), E2/drospirenone (45%), conjugated equine estrogens/medroxyprogesterone acetate (18-54%), ethinyl estradiol/NETA (31-61%), E2/levonorgestrel patch (16%), and E2/NETA patch (9-27%). Amenorrhea rates and the mean number of bleeding/spotting days improved over time. The oral E2/P4 combination was amongst those with lower bleeding rates and may be an appropriate alternative for millions of women seeking bioidentical HT and/or those who have bleeding concerns with other HT.

show abstract